National Institute of General Medical Sciences; Notice of Closed Meeting, 25804 [2017-11498]
Download as PDF
<![CDATA[
25804
Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK P01 Review.
Date: July 18, 2017.
Time: 4:00 p.m.to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Program Project on
Mucosal Immunology.
Date: July 25, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 7017, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davila-bloomm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–11495 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIGMS Initial Review
Group; Training and Workforce Development
Subcommittee—D; To review R25 Bridges to
Baccalaureate and K12 IRACDA Grant
applications.
Date: June 22–23, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Palomar, 2121 P Street NW.,
Washington, DC 20037.
Contact Person: Rebecca H. Johnson, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18C, Bethesda,
MD 20892, 301–594–2771, johnsonrh@
nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–11498 Filed 6–2–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Production of Attenuated
West Nile Virus Vaccines
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
VerDate Sep<11>2014
17:31 Jun 02, 2017
Jkt 241001
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to the
International Medica Foundation
located in Shoreview, Minnesota, U.S.A.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
SUMMARY:
National Institute of General Medical
Sciences; Notice of Closed Meeting
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Property Office on or before June 20,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Peter
Soukas, Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, National Institutes of Health,
5601 Fishers Lane, Suite 6D, Rockville,
MD 20852–9804; Email: ps193c@
nih.gov; Telephone: (301) 594–8730;
Facsimile: (240) 627–3117.
SUPPLEMENTARY INFORMATION:
Intellectual Property
E–357–2001/0,1, Pletnev et al.,
‘‘Construction of West Nile Virus and
Dengue Virus Chimeras for use in a Live
Virus Vaccine to Prevent Disease Cause
by West Nile Virus,’’ U.S. Provisional
Patent Application Number 60/347,281,
filed January 10, 2002, PCT Patent
Application Number PCT/US2003/
00594, filed January 9, 2003, U.S. Patent
Application Number 10/871,775 filed
June 18, 2004 (now U.S. Patent Number
8,778,671), U.S. Patent Application
Number 14/305,572, filed June 16, 2014,
European Patent Application Number
03729602.7, filed January 9, 2003,
Israeli Patent Application Number
162949, filed January 9, 2003 (now
Israeli Patent Number 162949),
Canadian Patent Application Number
2472468, filed January 9, 2003 (now
Canadian Patent Number 2472468),
Australian Patent Application Number
2003216046, filed January 9, 2003 (now
Australian Patent Number 2003216046),
Japanese Patent Application Number
2003–559545, filed January 9, 2003
(now Japanese Patent Number 4580650),
Australian Patent Application Number
2008203442 filed July 31, 2008 (now
Australian Patent Number 2008203442),
Israeli Patent Application Number
209342, filed January 9, 2003 (now
Israeli Patent Number 209342),
European Patent Application Number
11000126.0, filed January 9, 2003 (now
European Patent Number 2339011,
validated in Belgium, Great Britain, the
Netherlands, Norway, Germany,
Denmark and France), Australian Patent
Application Number 2011250694, filed
November 10, 2011 (now Australian
Patent Number 2011250694), Australian
Patent Application Number
2013213749, filed August 9, 2013,
European Patent Application Number
15163537.2, filed April 14, 2015, and
Canadian Patent Application Number
2903126, filed August 27, 2015, and
U.S. and foreign patent applications
E:\FR\FM\05JNN1.SGM
05JNN1
]]>Agencies
[Federal Register Volume 82, Number 106 (Monday, June 5, 2017)]
[Notices]
[Page 25804]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-11498]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: NIGMS Initial Review Group; Training and
Workforce Development Subcommittee--D; To review R25 Bridges to
Baccalaureate and K12 IRACDA Grant applications.
Date: June 22-23, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Palomar, 2121 P Street NW., Washington, DC 20037.
Contact Person: Rebecca H. Johnson, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Institute of General
Medical Sciences, National Institutes of Health, Natcher Building,
Room 3AN18C, Bethesda, MD 20892, 301-594-2771,
johnsonrh@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859, Biomedical Research and
Research Training, National Institutes of Health, HHS)
Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-11498 Filed 6-2-17; 8:45 am]
BILLING CODE 4140-01-P
